Author/Authors :
Baochun Zhang، نويسنده , , Sven Kracker، نويسنده , , Tomoharu Yasuda، نويسنده , , Stefano Casola، نويسنده , , Matthew Vanneman، نويسنده , , Cornelia H?mig-H?lzel، نويسنده , , Zhe Wang، نويسنده , , Emmanuel Derudder، نويسنده , , Shuang Li، نويسنده , , Tirtha Chakraborty، نويسنده , , Shane E. Cotter، نويسنده , , Shohei Koyama، نويسنده , , Treeve Currie، نويسنده , , Gordon J. Freeman، نويسنده , , Jeffery L. Kutok، نويسنده , , Scott J. Rodig، نويسنده , , Glenn Dranoff، نويسنده , , Klaus Rajewsky، نويسنده ,
Abstract :
B cells infected by Epstein-Barr virus (EBV), a transforming virus endemic in humans, are rapidly cleared by the immune system, but some cells harboring the virus persist for life. Under conditions of immunosuppression, EBV can spread from these cells and cause life-threatening pathologies. We have generated mice expressing the transforming EBV latent membrane protein 1 (LMP1), mimicking a constitutively active CD40 coreceptor, specifically in B cells. Like human EBV-infected cells, LMP1+ B cells were efficiently eliminated by T cells, and breaking immune surveillance resulted in rapid, fatal lymphoproliferation and lymphomagenesis. The lymphoma cells expressed ligands for a natural killer (NK) cell receptor, NKG2D, and could be targeted by an NKG2D-Fc fusion protein. These experiments indicate a central role for LMP1 in the surveillance and transformation of EBV-infected B cells in vivo, establish a preclinical model for B cell lymphomagenesis in immunosuppressed patients, and validate a new therapeutic approach.
